DK2593136T3 - Levende, svækket parvovirus - Google Patents
Levende, svækket parvovirus Download PDFInfo
- Publication number
- DK2593136T3 DK2593136T3 DK11732480.6T DK11732480T DK2593136T3 DK 2593136 T3 DK2593136 T3 DK 2593136T3 DK 11732480 T DK11732480 T DK 11732480T DK 2593136 T3 DK2593136 T3 DK 2593136T3
- Authority
- DK
- Denmark
- Prior art keywords
- amino acid
- parvovirus
- cpv2
- encoding
- capsid
- Prior art date
Links
- 241000125945 Protoparvovirus Species 0.000 title claims description 52
- 241000700605 Viruses Species 0.000 claims description 65
- 150000001413 amino acids Chemical class 0.000 claims description 58
- 239000012634 fragment Substances 0.000 claims description 48
- 210000000234 capsid Anatomy 0.000 claims description 43
- 229960005486 vaccine Drugs 0.000 claims description 36
- 230000002238 attenuated effect Effects 0.000 claims description 35
- 241000701931 Canine parvovirus Species 0.000 claims description 34
- 108090000623 proteins and genes Proteins 0.000 claims description 32
- 108020004414 DNA Proteins 0.000 claims description 29
- 108090000565 Capsid Proteins Proteins 0.000 claims description 28
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 28
- 229940024606 amino acid Drugs 0.000 claims description 24
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 17
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 17
- 229960000310 isoleucine Drugs 0.000 claims description 17
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 108020004705 Codon Proteins 0.000 claims description 13
- 208000015181 infectious disease Diseases 0.000 claims description 13
- 230000035772 mutation Effects 0.000 claims description 13
- 241000282465 Canis Species 0.000 claims description 11
- 244000005700 microbiome Species 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 8
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 230000001717 pathogenic effect Effects 0.000 claims description 6
- 229940001442 combination vaccine Drugs 0.000 claims description 5
- 230000002163 immunogen Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- 208000008071 Parvoviridae Infections Diseases 0.000 claims description 3
- 206010057343 Parvovirus infection Diseases 0.000 claims description 3
- 241000711798 Rabies lyssavirus Species 0.000 claims description 3
- 230000002068 genetic effect Effects 0.000 claims description 3
- 239000004474 valine Substances 0.000 claims description 3
- 241001466447 Babesia gibsoni Species 0.000 claims description 2
- 241000701157 Canine mastadenovirus A Species 0.000 claims description 2
- 241000712083 Canine morbillivirus Species 0.000 claims description 2
- 241001647374 Chlamydia felis Species 0.000 claims description 2
- 241000605312 Ehrlichia canis Species 0.000 claims description 2
- 241001550390 Leptospira interrogans serovar Canicola Species 0.000 claims description 2
- 108020004511 Recombinant DNA Proteins 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229940051998 ehrlichia canis Drugs 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 241000589968 Borrelia Species 0.000 claims 1
- 241000711573 Coronaviridae Species 0.000 claims 1
- 241000222727 Leishmania donovani Species 0.000 claims 1
- 208000016604 Lyme disease Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 description 36
- 239000013612 plasmid Substances 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 18
- 241000282472 Canis lupus familiaris Species 0.000 description 16
- 238000010276 construction Methods 0.000 description 11
- 241000282326 Felis catus Species 0.000 description 10
- 230000002458 infectious effect Effects 0.000 description 9
- 108091008146 restriction endonucleases Proteins 0.000 description 9
- 238000001890 transfection Methods 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 241000282324 Felis Species 0.000 description 6
- 108020005202 Viral DNA Proteins 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 239000000872 buffer Substances 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 208000002613 Feline Panleukopenia Diseases 0.000 description 3
- 241000701925 Feline parvovirus Species 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 208000005093 cerebellar hypoplasia Diseases 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000001712 DNA sequencing Methods 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000701915 Feline panleukopenia virus Species 0.000 description 2
- 239000012097 Lipofectamine 2000 Substances 0.000 description 2
- 241000987543 Martella Species 0.000 description 2
- 241000702619 Porcine parvovirus Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 101000909800 Xenopus laevis Probable N-acetyltransferase camello Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- CWPDVLMKCHLLPS-JVPBZIDWSA-N 2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]acetic acid Chemical compound C([C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(O)=O)C1=CC=C(O)C=C1 CWPDVLMKCHLLPS-JVPBZIDWSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000025906 Aleutian Mink Disease Diseases 0.000 description 1
- 238000006677 Appel reaction Methods 0.000 description 1
- RYRQZJVFDVWURI-SRVKXCTJSA-N Arg-Gln-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCN=C(N)N)N RYRQZJVFDVWURI-SRVKXCTJSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000588779 Bordetella bronchiseptica Species 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 241000711506 Canine coronavirus Species 0.000 description 1
- 241001353878 Canine parainfluenza virus Species 0.000 description 1
- 241001466804 Carnivora Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000000655 Distemper Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000701087 Felid alphaherpesvirus 1 Species 0.000 description 1
- 241000714201 Feline calicivirus Species 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- VEPBEGNDJYANCF-QWRGUYRKSA-N Gly-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCCN VEPBEGNDJYANCF-QWRGUYRKSA-N 0.000 description 1
- 241000149124 Hepatozoon canis Species 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000702625 Mink enteritis virus Species 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- 241000282331 Mustelidae Species 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- RNEFESSBTOQSAC-DCAQKATOSA-N Pro-Ser-His Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O RNEFESSBTOQSAC-DCAQKATOSA-N 0.000 description 1
- 241000282335 Procyon Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- AQAMPXBRJJWPNI-JHEQGTHGSA-N Thr-Gly-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O AQAMPXBRJJWPNI-JHEQGTHGSA-N 0.000 description 1
- KBBRNEDOYWMIJP-KYNKHSRBSA-N Thr-Gly-Thr Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)O KBBRNEDOYWMIJP-KYNKHSRBSA-N 0.000 description 1
- KZSYAEWQMJEGRZ-RHYQMDGZSA-N Thr-Leu-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O KZSYAEWQMJEGRZ-RHYQMDGZSA-N 0.000 description 1
- COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- GKUROEIXVURAAO-BPUTZDHNSA-N Trp-Asp-Arg Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GKUROEIXVURAAO-BPUTZDHNSA-N 0.000 description 1
- FDKDGFGTHGJKNV-FHWLQOOXSA-N Tyr-Phe-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N FDKDGFGTHGJKNV-FHWLQOOXSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229910000318 alkali metal phosphate Inorganic materials 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008011 embryonic death Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 108010036413 histidylglycine Proteins 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 208000002254 stillbirth Diseases 0.000 description 1
- 231100000537 stillbirth Toxicity 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 108010025432 tyrosyl-alanyl-phenylalanyl-glycine Proteins 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14311—Parvovirus, e.g. minute virus of mice
- C12N2750/14322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14311—Parvovirus, e.g. minute virus of mice
- C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14311—Parvovirus, e.g. minute virus of mice
- C12N2750/14341—Use of virus, viral particle or viral elements as a vector
- C12N2750/14343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14311—Parvovirus, e.g. minute virus of mice
- C12N2750/14361—Methods of inactivation or attenuation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Claims (12)
- LEVENDE, SV2EKKET PARVOVIRUS1. Levende, svaekket CPV2-parvovirus, kendetegnet ved, at CPV2 omfatter et capsidgen af CPV2 serotype 2a, 2b eller 2c, der koder for en anden aminosyre end isoleucin ved aminosyreposition 219 af capsidproteinet og/eller en anden aminosyre end glutamin ved aminosyreposition 386 af eapsidproteinet, og kendetegnet ved, at et DNA-fragment af en del af ikke-capsidomrádet af CPV2 udskiftes af et homologt DNA-fragment af en del af ikke-capsidomrádet afledt af et andet parvovirus, hvor det homologe DNA-fragment af det andet parvovirus baerer en svaskkende mutation.
- 2. Levende, svaskket CPV2 ifolge krav 1, kendetegnet ved, at CPV2 omfatter et capsidgen, der koder for en anden aminosyre end isoleucin ved aminosyreposition 219 af capsidproteinet, og en anden aminosyre end glutamin ved aminosyreposition 386 af capsidproteinet.
- 3. Levende, svaskket CPV2 ifolge krav 2, kendetegnet ved, at CPV2 omfatter et capsidgen, der koder for et valin ved aminosyreposition 219 af capsidproteinet og/eller et lysin ved aminosyreposition 386 af capsidproteinet.
- 4. Levende, svcekket CPV2-parvovirus ifolge et hvilket som helst af kravene 1-3, kendetegnet ved, at det homologe DNA-fragment af det andet parvovirus basrer en svaakkende mutation i det ikke-strukturelle ornráde, i omrádet fra position 2061 til 2070 ifolge SEQ ID NO: 1.
- 5. Vaccine til beskyttelse af dyr mod infektion med CPV2-parvovirus, kendetegnet ved, at vaccinen omfatter et levende, svaekket CPV2-parvovirus ifolge et hvilket som helst af kravene 1-4 og en farmaceutisk acceptabel basrer.
- 6. Kombinationsvaccine til beskyttelse af dyr mod patogener, kendetegnet ved, at kombinationsvaccinen omfatter en vaccine ifolge krav 5 og et supplerende antigen af et virus eller en mikroorganisme, der er patogenEpatogen for dyr, eller genetiske informationer, der koder for et immunogent protein af virusset eller mikroorganismen.
- 7. Kombinationsvaccine ifolge krav 6, kendetegnet ved, at virusset eller mikroorganismen, der er patogent/patogen for dyr, er udvalgt fra gruppen bestáende af Ehrlichia canis, Babesia gibsoni, vogeli, rossi, Leishmania donovani-complex, hunde-adenovirus, hunde-coronavirus, hunde-distempervirus, Leptospira interrogans serovar canicola, icterohaemorrhagiae, pomona, grippotyphosa, bratislava, hunde-hcpatitisvirus, hunde-parainflucnzavims, rabiesvirus, Hepatozoon canis, Borrelia burgdorferi, Bordetella bronchiseptica, katte-herpesvirus, katte-calicivirus, katte-panleucopeni og Chlamydophila felis.
- 8. Fremgangsmáde til fremstilling af en vaccine ifolge krav 5 eller en kombinationsvaccine ifolge krav 6 eller 7, kendetegnet ved, at fremgangsmáden omfatter blanding af et levende, svaskket CPV2-parvovirus ifolge et hvilket som helst af kravene 1-4 og en farmaceutisk acceptabel basrer.
- 9. Levende, svaskket CPV2-parvovirus ifolge et hvilket som helst af kravene 1-4 til anvendelse som et medikament.
- 10. Levende, svaskket CPV2-parvovirus ifolge et hvilket som helst af kravene 1-4 til anvendelse i behandlingen af en parvovirusinfektion.
- 11. Fremgangsmáde til fremstilling af en CPV2-parvovirusmutant ifolge et hvilket som helst af kravene 1-4, kendetegnet ved, at fremgangsmáden omfatter trinnet med asndring i et gen, der koder for et capsidprotein af CPV2 serotype 2a, 2b eller 2c, af et hunde-parvovirus, der allerede er svackket i en anden del end den del, der koder for capsidet, ved rekombinante DNA-teknikker, et codon ved aminosyreposition 219, der koder for isoleucin og/eller et codon ved amino syreposition 386, der koder for glutamin, ind i et codon ved amino syreposition 219, der koder for en anden aminosyre end isoleucin og/eller et codon, der koder for en anden aminosyre end glutamin ved amino syreposition 386.
- 12. Fremgangsmáde til fremstilling af en CPV2-parvovirusmutant ifolge et hvilket som helst af kravene 1-4, kendetegnet ved, at fremgangsmáden omfatter udskiftning i et gen, der koder for et capsidprotein af CPV2 serotype 2a, 2b eller 2c, af et hunde-parvovirus, der allerede er svaskket i en anden del end den del, der koder for capsidet, et DNA-fragment, der koder for mindst en del af parvo viruscapsidprotein, der ved amino syreposition 219 har et codon, der koder for isoleucin og/eller ved amino syreposition 386 har et codon, der koder for glutamin, med et DNA-fragment, der koder for den samme del af parvoviruscapsidproteinet, der nu ved aminosyreposition 219 har et codon, der koder for en anden aminosyre end isoleucin og/eller ved aminosyreposition 386 har et codon, der koder for en anden aminosyre end glutamin.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10169872 | 2010-07-16 | ||
| US36568410P | 2010-07-19 | 2010-07-19 | |
| PCT/EP2011/062203 WO2012007589A1 (en) | 2010-07-16 | 2011-07-18 | Live attenuated parvovirus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2593136T3 true DK2593136T3 (da) | 2017-05-08 |
Family
ID=42629432
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11732480.6T DK2593136T3 (da) | 2010-07-16 | 2011-07-18 | Levende, svækket parvovirus |
| DK17156212.7T DK3199178T3 (da) | 2010-07-16 | 2011-07-18 | Levende, svækket parvovirus |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17156212.7T DK3199178T3 (da) | 2010-07-16 | 2011-07-18 | Levende, svækket parvovirus |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9186398B2 (da) |
| EP (2) | EP2593136B1 (da) |
| JP (2) | JP6061850B2 (da) |
| CN (2) | CN107254451B (da) |
| BR (2) | BR122021023230B8 (da) |
| CA (1) | CA2802283C (da) |
| DK (2) | DK2593136T3 (da) |
| ES (1) | ES2623149T3 (da) |
| FR (1) | FR21C1022I2 (da) |
| NL (1) | NL301108I2 (da) |
| PT (1) | PT2593136T (da) |
| WO (1) | WO2012007589A1 (da) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR122021023230B8 (pt) * | 2010-07-16 | 2023-12-12 | Intervet Int Bv | Vacina de combinação que compreende uma vacina compreendendo um parvovírus vivo atenuado |
| US9314519B2 (en) | 2012-08-21 | 2016-04-19 | Intervet Inc. | Liquid stable virus vaccines |
| CN104812893B (zh) * | 2012-11-22 | 2018-08-03 | 旭化成医疗株式会社 | 高感染滴度的细小病毒的生产方法 |
| CA2892221A1 (en) * | 2012-12-19 | 2014-06-26 | Intervet International B.V. | Canine parvovirus type 2c isolates and methods of use |
| AR097762A1 (es) | 2013-09-27 | 2016-04-13 | Intervet Int Bv | Formulaciones secas de vacunas que son estables a temperatura ambiente |
| JP6414409B2 (ja) * | 2014-07-29 | 2018-10-31 | 株式会社微生物化学研究所 | 弱毒化パルボウイルスおよび弱毒化パルボウイルスを用いたワクチン |
| CN109735505A (zh) * | 2018-12-26 | 2019-05-10 | 河南农业大学 | 一株犬细小病毒毒株及其基因序列的扩增和应用 |
| CN110845582B (zh) * | 2019-12-23 | 2021-07-23 | 杭州贤至生物科技有限公司 | 一种猫细小病毒重组蛋白及其单克隆抗体的制备 |
| WO2022096472A1 (en) | 2020-11-04 | 2022-05-12 | Intervet International B.V. | Canine parvovirus |
| CN114426956B (zh) * | 2022-02-08 | 2023-11-17 | 辽宁益康生物股份有限公司 | 猫狂犬病泛白细胞减少症鼻气管炎鼻结膜炎四联灭活疫苗 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5814510A (en) * | 1994-11-08 | 1998-09-29 | Cornell Research Foundation, Inc. | Attenuated canine parvovirus vaccine |
| US5885585A (en) * | 1994-11-08 | 1999-03-23 | Cornell Research Foundation, Inc. | Attenuated canine parvovirus vaccine |
| EP2158211B1 (en) * | 2007-05-31 | 2016-08-10 | Medigene AG | Mutated structural protein of a parvovirus |
| EP2012122A1 (en) * | 2007-07-06 | 2009-01-07 | Medigene AG | Mutated parvovirus structural proteins as vaccines |
| CN106048082A (zh) * | 2007-06-14 | 2016-10-26 | 俄克拉荷马州大学评议会 | 包含犬细小病毒遗传性变体的疫苗 |
| BR122021023230B8 (pt) * | 2010-07-16 | 2023-12-12 | Intervet Int Bv | Vacina de combinação que compreende uma vacina compreendendo um parvovírus vivo atenuado |
-
2011
- 2011-07-18 BR BR122021023230A patent/BR122021023230B8/pt active IP Right Grant
- 2011-07-18 CN CN201710646762.2A patent/CN107254451B/zh active Active
- 2011-07-18 EP EP11732480.6A patent/EP2593136B1/en active Active
- 2011-07-18 US US13/810,349 patent/US9186398B2/en active Active
- 2011-07-18 PT PT117324806T patent/PT2593136T/pt unknown
- 2011-07-18 DK DK11732480.6T patent/DK2593136T3/da active
- 2011-07-18 DK DK17156212.7T patent/DK3199178T3/da active
- 2011-07-18 ES ES11732480.6T patent/ES2623149T3/es active Active
- 2011-07-18 CN CN201180034991XA patent/CN102985108A/zh active Pending
- 2011-07-18 CA CA2802283A patent/CA2802283C/en active Active
- 2011-07-18 EP EP17156212.7A patent/EP3199178B1/en active Active
- 2011-07-18 JP JP2013519115A patent/JP6061850B2/ja active Active
- 2011-07-18 WO PCT/EP2011/062203 patent/WO2012007589A1/en not_active Ceased
- 2011-07-18 BR BR112012030659A patent/BR112012030659B8/pt active IP Right Grant
-
2016
- 2016-07-27 JP JP2016147811A patent/JP6298499B2/ja active Active
-
2021
- 2021-06-04 NL NL301108C patent/NL301108I2/nl unknown
- 2021-06-08 FR FR21C1022C patent/FR21C1022I2/fr active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DK3199178T3 (da) | 2020-04-14 |
| EP2593136A1 (en) | 2013-05-22 |
| BR112012030659B1 (pt) | 2021-12-21 |
| CA2802283C (en) | 2018-06-05 |
| CN107254451B (zh) | 2021-12-10 |
| ES2623149T3 (es) | 2017-07-10 |
| BR122021023230B8 (pt) | 2023-12-12 |
| CN107254451A (zh) | 2017-10-17 |
| BR122021023230B1 (pt) | 2023-01-17 |
| JP6298499B2 (ja) | 2018-03-20 |
| FR21C1022I1 (fr) | 2021-07-16 |
| EP2593136B1 (en) | 2017-03-08 |
| BR112012030659B8 (pt) | 2022-10-04 |
| NL301108I2 (nl) | 2024-01-29 |
| WO2012007589A1 (en) | 2012-01-19 |
| JP2013535188A (ja) | 2013-09-12 |
| EP3199178A1 (en) | 2017-08-02 |
| BR112012030659A8 (pt) | 2021-09-28 |
| US20130195913A1 (en) | 2013-08-01 |
| EP3199178B1 (en) | 2020-02-19 |
| JP6061850B2 (ja) | 2017-01-25 |
| US9186398B2 (en) | 2015-11-17 |
| CN102985108A (zh) | 2013-03-20 |
| FR21C1022I2 (fr) | 2024-03-29 |
| CA2802283A1 (en) | 2012-01-19 |
| JP2017029140A (ja) | 2017-02-09 |
| BR112012030659A2 (pt) | 2017-01-24 |
| PT2593136T (pt) | 2017-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2593136T3 (da) | Levende, svækket parvovirus | |
| DK2542260T3 (da) | Rekombinant svækket parvovirus | |
| JP2022120083A (ja) | ブタサーコウイルス３型免疫原性組成物、その製造方法、およびその使用方法 | |
| AU2020277165B2 (en) | Feline calicivirus vaccine | |
| KR101320192B1 (ko) | 토크 테노 바이러스(ｔｔｖ) 분리물 및 조성물 | |
| US20230405110A1 (en) | Canine Parvovirus | |
| ES2783898T3 (es) | Parvovirus atenuado vivo | |
| BR112012021650B1 (pt) | Parvovírus recombinante atenuado, vacina para a proteção de animais contra infecção com parvovírus, método para a obtenção do referido parvovírus recombinante e seu uso |